Now showing items 1-20 of 73

    • 18F-FDG PET/CT Optimizes Treatment in Staphylococcus Aureus Bacteremia and Is Associated with Reduced Mortality. 

      Berrevoets, MAH; Kouijzer, IJE; Aarntzen, EHJG; Janssen, MJR; De Geus-Oei, L-F; Wertheim, HFL; Kullberg, B-J; Oever, JT; Oyen, WJG; Bleeker-Rovers, CP (2017-09)
      Metastatic infection is an important complication of Staphylococcus aureus bacteremia (SAB). Early diagnosis of metastatic infection is crucial, because specific treatment is required. However, metastatic infection can be ...
    • Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor. 

      Desar, IME; Braam, PM; Kaal, SEJ; Gerritsen, WR; Oyen, WJG; van der Graaf, WTA (2016-12)
    • Activity and safety of crizotinib in patients with advanced clear-cell sarcoma with MET alterations: European Organization for Research and Treatment of Cancer phase II trial 90101 'CREATE'. 

      Schöffski, P; Wozniak, A; Stacchiotti, S; Rutkowski, P; Blay, J-Y; Lindner, LH; Strauss, SJ; Anthoney, A; Duffaud, F; Richter, S; Grünwald, V; Leahy, MG; Reichardt, P; Sufliarsky, J; van der Graaf, WT; Sciot, R; Debiec-Rychter, M; van Cann, T; Marréaud, S; Lia, M; Raveloarivahy, T; Collette, L; Bauer, S (2017-12-01)
      Background: Clear-cell sarcoma (CCSA) is an orphan malignancy, characterized by a specific t(12;22) translocation, leading to rearrangement of the EWSR1 gene and overexpression of MET. We prospectively investigated the ...
    • Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. 

      Long, GV; Hauschild, A; Santinami, M; Atkinson, V; Mandalà, M; Chiarion-Sileni, V; Larkin, J; Nyakas, M; Dutriaux, C; Haydon, A; Robert, C; Mortier, L; Schachter, J; Schadendorf, D; Lesimple, T; Plummer, R; Ji, R; Zhang, P; Mookerjee, B; Legos, J; Kefford, R; Dummer, R; Kirkwood, JM (2017-11-09)
      BACKGROUND: Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant ...
    • Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. 

      Weber, J; Mandala, M; Del Vecchio, M; Gogas, HJ; Arance, AM; Cowey, CL; Dalle, S; Schenker, M; Chiarion-Sileni, V; Marquez-Rodas, I; Grob, J-J; Butler, MO; Middleton, MR; Maio, M; Atkinson, V; Queirolo, P; Gonzalez, R; Kudchadkar, RR; Smylie, M; Meyer, N; Mortier, L; Atkins, MB; Long, GV; Bhatia, S; Lebbé, C; Rutkowski, P; Yokota, K; Yamazaki, N; Kim, TM; de Pril, V; Sabater, J; Qureshi, A; Larkin, J; Ascierto, PA; CheckMate 238 Collaborators (2017-11-09)
      BACKGROUND: Nivolumab and ipilimumab are immune checkpoint inhibitors that have been approved for the treatment of advanced melanoma. In the United States, ipilimumab has also been approved as adjuvant therapy for melanoma ...
    • Adolescent and young adult (AYA) lymphoma survivors report lower health-related quality of life compared to a normative population: results from the PROFILES registry. 

      Husson, O; Prins, JB; Kaal, SEJ; Oerlemans, S; Stevens, WB; Zebrack, B; van der Graaf, WTA; van de Poll-Franse, LV (2017-02)
      BACKGROUND: Trying to simultaneously achieve developmental milestones and cope with a life-threatening disease may place adolescents and young adults (AYAs) at risk for impaired health-related quality of life (HRQoL) later ...
    • Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW. 

      Muro, K; Cho, JY; Bodoky, G; Goswami, C; Chao, Y; Dos Santos, LV; Shimada, Y; Topuzov, E; Van Cutsem, E; Tabernero, J; Zalcberg, J; Chau, I; Cascinu, S; Cheng, R; Hsu, Y; Emig, M; Orlando, M; Fuchs, C (2018-04)
      BACKGROUND AND AIM: REGARD and RAINBOW were global, phase 3, randomized, double-blind trials of second-line ramucirumab for metastatic gastric or gastroesophageal junction adenocarcinoma. Exploratory subgroup analyses were ...
    • Baseline results from the UK SIGNIFY study: a whole-body MRI screening study in TP53 mutation carriers and matched controls. 

      Saya, S; Killick, E; Thomas, S; Taylor, N; Bancroft, EK; Rothwell, J; Benafif, S; Dias, A; Mikropoulos, C; Pope, J; Chamberlain, A; Gunapala, R; SIGNIFY Study Steering Committee; Izatt, L; Side, L; Walker, L; Tomkins, S; Cook, J; Barwell, J; Wiles, V; Limb, L; Eccles, D; Leach, MO; Shanley, S; Gilbert, FJ; Hanson, H; Gallagher, D; Rajashanker, B; Whitehouse, RW; Koh, D-M; Sohaib, SA; Evans, DG; Eeles, RA (2017-07)
      In the United Kingdom, current screening guidelines for TP53 germline mutation carriers solely recommends annual breast MRI, despite the wide spectrum of malignancies typically seen in this group. This study sought to ...
    • Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. 

      Ladenstein, R; Pötschger, U; Pearson, ADJ; Brock, P; Luksch, R; Castel, V; Yaniv, I; Papadakis, V; Laureys, G; Malis, J; Balwierz, W; Ruud, E; Kogner, P; Schroeder, H; de Lacerda, AF; Beck-Popovic, M; Bician, P; Garami, M; Trahair, T; Canete, A; Ambros, PF; Holmes, K; Gaze, M; Schreier, G; Garaventa, A; Vassal, G; Michon, J; Valteau-Couanet, D; SIOP Europe Neuroblastoma Group (SIOPEN) (2017-04)
      BACKGROUND: High-dose chemotherapy with haemopoietic stem-cell rescue improves event-free survival in patients with high-risk neuroblastoma; however, which regimen has the greatest patient benefit has not been established. ...
    • Cancer Risks in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study. 

      Swerdlow, AJ; Cooke, R; Beckers, D; Borgström, B; Butler, G; Carel, J-C; Cianfarani, S; Clayton, P; Coste, J; Deodati, A; Ecosse, E; Gausche, R; Giacomozzi, C; Hokken-Koelega, ACS; Khan, AJ; Kiess, W; Kuehni, CE; Mullis, P-E; Pfaffle, R; Sävendahl, L; Sommer, G; Thomas, M; Tidblad, A; Tollerfield, S; Van Eycken, L; Zandwijken, GRJ (2017-05-01)
      Context: Growth hormone (GH) is prescribed for an increasing range of indications, but there has been concern that it might raise cancer risk. Published data are limited. Objective: To examine cancer risks in relation to ...
    • Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. 

      Peterlongo, P; Chang-Claude, J; Moysich, KB; Rudolph, A; Schmutzler, RK; Simard, J; Soucy, P; Eeles, RA; Easton, DF; Hamann, U; Wilkening, S; Chen, B; Rookus, MA; Schmidt, MK; van der Baan, FH; Spurdle, AB; Walker, LC; Lose, F; Maia, AT; Montagna, M; Matricardi, L; Lubinski, J; Jakubowska, A; Gómez Garcia, EB; Olopade, OI; Nussbaum, RL; Nathanson, KL; Domchek, SM; Rebbeck, TR; Arun, BK; Karlan, BY; Orsulic, S; Lester, J; Chung, WK; Miron, A; Southey, MC; Goldgar, DE; Buys, SS; Janavicius, R; Dorfling, CM; van Rensburg, EJ; Ding, YC; Neuhausen, SL; Hansen, TV; Gerdes, AM; Ejlertsen, B; Jønson, L; Osorio, A; Martínez-Bouzas, C; Benitez, J; Conway, EE; Blazer, KR; Weitzel, JN; Manoukian, S; Peissel, B; Zaffaroni, D; Scuvera, G; Barile, M; Ficarazzi, F; Mariette, F; Fortuzzi, S; Viel, A; Giannini, G; Papi, L; Martayan, A; Tibiletti, MG; Radice, P; Vratimos, A; Fostira, F; Garber, JE; Donaldson, A; Brewer, C; Foo, C; Evans, DG; Frost, D; Eccles, D; Brady, A; Cook, J; Tischkowitz, M; Adlard, J; Barwell, J; Walker, L; Izatt, L; Side, LE; Kennedy, MJ; Rogers, MT; Porteous, ME; Morrison, PJ; Platte, R; Davidson, R; Hodgson, SV; Ellis, S; Cole, T; Godwin, AK; Claes, K; Van Maerken, T; Meindl, A; Gehrig, A; Sutter, C; Engel, C; Niederacher, D; Steinemann, D; Plendl, H; Kast, K; Rhiem, K; Ditsch, N; Arnold, N; Varon-Mateeva, R; Wappenschmidt, B; Wang-Gohrke, S; Bressac-de Paillerets, B; Buecher, B; Delnatte, C; Houdayer, C; Stoppa-Lyonnet, D; Damiola, F; Coupier, I; Barjhoux, L; Venat-Bouvet, L; Golmard, L; Boutry-Kryza, N; Sinilnikova, OM; Caron, O; Pujol, P; Mazoyer, S; Belotti, M; Piedmonte, M; Friedlander, ML; Rodriguez, GC; Copeland, LJ; de la Hoya, M; Segura, PP; Nevanlinna, H; Aittomäki, K; van Os, TA; Meijers-Heijboer, HE; van der Hout, AH; Vreeswijk, MP; Hoogerbrugge, N; Ausems, MG; van Doorn, HC; Collée, JM; Olah, E; Diez, O; Blanco, I; Lazaro, C; Brunet, J; Feliubadalo, L; Cybulski, C; Gronwald, J; Durda, K; Jaworska-Bieniek, K; Sukiennicki, G; Arason, A; Chiquette, J; Teixeira, MR; Olswold, C; Couch, FJ; Lindor, NM; Wang, X; Szabo, CI; Offit, K; Corines, M; Jacobs, L; Robson, ME; Zhang, L; Joseph, V; Joseph, V; Berger, A; Singer, CF; Rappaport, C; Kaulich, DG; Pfeiler, G; Tea, MK; Phelan, CM; Greene, MH; Mai, PL; Rennert, G; Mulligan, AM; Glendon, G; Tchatchou, S; Andrulis, IL; Toland, AE; Bojesen, A; Pedersen, IS; Thomassen, M; Jensen, UB; Laitman, Y; Rantala, J; von Wachenfeldt, A; Ehrencrona, H; Askmalm, MS; Borg, Å; Kuchenbaecker, KB; McGuffog, L; Barrowdale, D; Healey, S; Lee, A; Pharoah, PD; Chenevix-Trench, G; Antoniou, AC; Friedman, E (2015-01)
      BRCA1 and BRCA2 mutation carriers are at substantially increased risk for developing breast and ovarian cancer. The incomplete penetrance coupled with the variable age at diagnosis in carriers of the same mutation suggests ...
    • CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. 

      Locke, FL; Pidala, J; Storer, B; Martin, PJ; Pulsipher, MA; Chauncey, TR; Jacobsen, N; Kröger, N; Walker, I; Light, S; Shaw, BE; Beato, F; Laport, GG; Nademanee, A; Keating, A; Socie, G; Anasetti, C (2017-03)
      Daclizumab, a humanized monoclonal antibody, binds CD25 and blocks formation of the IL-2 receptor on T cells. A study of daclizumab as acute graft-versus-host disease (GVHD) prophylaxis after unrelated bone marrow ...
    • Chemotherapy with radiotherapy influences time-to-development of radiation-induced sarcomas: a multicenter study. 

      Zhang, AY; Judson, I; Benson, C; Wunder, JS; Ray-Coquard, I; Grimer, RJ; Quek, R; Wong, E; Miah, AB; Ferguson, PC; Dufresne, A; Teh, JYH; Stockler, M; Tattersall, MHN (2017-07-25)
      BACKGROUND: An increasing number and proportion of cancer patients with apparently localised disease are treated with chemotherapy and radiation therapy in contemporary oncology practice. In a pilot study of radiation-induced ...
    • Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients. 

      Farag, S; Somaiah, N; Choi, H; Heeres, B; Wang, W-L; van Boven, H; Nederlof, P; Benjamin, R; van der Graaf, W; Grunhagen, D; Boonstra, PA; Reyners, AKL; Gelderblom, H; Steeghs, N (2017-05)
      PURPOSE: Patients, platelet-derived growth factor receptor alpha (PDGFRA) D842V-mutated gastrointestinal stromal tumours (GISTs) are known for their insensitivity to imatinib. However, in clinical practice responses have ...
    • COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss. 

      Crabb, SJ; Martin, K; Abab, J; Ratcliffe, I; Thornton, R; Lineton, B; Ellis, M; Moody, R; Stanton, L; Galanopoulou, A; Maishman, T; Geldart, T; Bayne, M; Davies, J; Lamb, C; Popat, S; Joffe, JK; Nutting, C; Chester, J; Hartley, A; Thomas, G; Ottensmeier, C; Huddart, R; King, E (2017-12)
      BACKGROUND: Cisplatin is one of the most ototoxic chemotherapy drugs, resulting in a permanent and irreversible hearing loss in up to 50% of patients. Cisplatin and gentamicin are thought to damage hearing through a common ...
    • Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. 

      Geuna, E; Roda, D; Rafii, S; Jimenez, B; Capelan, M; Rihawi, K; Montemurro, F; Yap, TA; Kaye, SB; De Bono, JS; Molife, LR; Banerji, U (2015-12)
      PI3K-AKT-mTOR inhibitors (PAMi) are promising anticancer treatments. Hyperglycaemia is a mechanism-based toxicity of these agents and is becoming increasingly important with their use in larger numbers of patients.Retrospective ...
    • CYP3A7*1C allele is associated with reduced levels of 2-hydroxylation pathway oestrogen metabolites. 

      Sood, D; Johnson, N; Jain, P; Siskos, AP; Bennett, M; Gilham, C; Busana, MC; Peto, J; Dos-Santos-Silva, I; Keun, HC; Fletcher, O (2017-01)
      BACKGROUND: Endogenous sex hormones are well-established risk factors for breast cancer; the contribution of specific oestrogen metabolites (EMs) and/or ratios of specific EMs is less clear. We have previously identified ...
    • Desmoplastic small round cell tumor: evaluation of reverse transcription-polymerase chain reaction and fluorescence in situ hybridization as ancillary molecular diagnostic techniques. 

      Mohamed, M; Gonzalez, D; Fritchie, KJ; Swansbury, J; Wren, D; Benson, C; Jones, RL; Fisher, C; Thway, K (2017-11)
      Desmoplastic small round cell tumor (DSRCT) is a rare, biologically aggressive soft tissue neoplasm of uncertain differentiation, most often arising in the abdominal and pelvic cavities of adolescents and young adults with ...
    • Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. 

      Veldhuijzen van Zanten, SEM; Baugh, J; Chaney, B; De Jongh, D; Sanchez Aliaga, E; Barkhof, F; Noltes, J; De Wolf, R; Van Dijk, J; Cannarozzo, A; Damen-Korbijn, CM; Lieverst, JA; Colditz, N; Hoffmann, M; Warmuth-Metz, M; Bison, B; Jones, DTW; Sturm, D; Gielen, GH; Jones, C; Hulleman, E; Calmon, R; Castel, D; Varlet, P; Giraud, G; Slavc, I; Van Gool, S; Jacobs, S; Jadrijevic-Cvrlje, F; Sumerauer, D; Nysom, K; Pentikainen, V; Kivivuori, S-M; Leblond, P; Entz-Werle, N; von Bueren, AO; Kattamis, A; Hargrave, DR; Hauser, P; Garami, M; Thorarinsdottir, HK; Pears, J; Gandola, L; Rutkauskiene, G; Janssens, GO; Torsvik, IK; Perek-Polnik, M; Gil-da-Costa, MJ; Zheludkova, O; Shats, L; Deak, L; Kitanovski, L; Cruz, O; Morales La Madrid, A; Holm, S; Gerber, N; Kebudi, R; Grundy, R; Lopez-Aguilar, E; Zapata-Tarres, M; Emmerik, J; Hayden, T; Bailey, S; Biassoni, V; Massimino, M; Grill, J; Vandertop, WP; Kaspers, GJL; Fouladi, M; Kramm, CM; van Vuurden, DG; members of the SIOPE DIPG Network (2017-04)
      Diffuse intrinsic pontine glioma (DIPG) is a rare and deadly childhood malignancy. After 40 years of mostly single-center, often non-randomized trials with variable patient inclusions, there has been no improvement in ...
    • DNA methylation-based classification of central nervous system tumours. 

      Capper, D; Jones, DTW; Sill, M; Hovestadt, V; Schrimpf, D; Sturm, D; Koelsche, C; Sahm, F; Chavez, L; Reuss, DE; Kratz, A; Wefers, AK; Huang, K; Pajtler, KW; Schweizer, L; Stichel, D; Olar, A; Engel, NW; Lindenberg, K; Harter, PN; Braczynski, AK; Plate, KH; Dohmen, H; Garvalov, BK; Coras, R; Hölsken, A; Hewer, E; Bewerunge-Hudler, M; Schick, M; Fischer, R; Beschorner, R; Schittenhelm, J; Staszewski, O; Wani, K; Varlet, P; Pages, M; Temming, P; Lohmann, D; Selt, F; Witt, H; Milde, T; Witt, O; Aronica, E; Giangaspero, F; Rushing, E; Scheurlen, W; Geisenberger, C; Rodriguez, FJ; Becker, A; Preusser, M; Haberler, C; Bjerkvig, R; Cryan, J; Farrell, M; Deckert, M; Hench, J; Frank, S; Serrano, J; Kannan, K; Tsirigos, A; Brück, W; Hofer, S; Brehmer, S; Seiz-Rosenhagen, M; Hänggi, D; Hans, V; Rozsnoki, S; Hansford, JR; Kohlhof, P; Kristensen, BW; Lechner, M; Lopes, B; Mawrin, C; Ketter, R; Kulozik, A; Khatib, Z; Heppner, F; Koch, A; Jouvet, A; Keohane, C; Mühleisen, H; Mueller, W; Pohl, U; Prinz, M; Benner, A; Zapatka, M; Gottardo, NG; Driever, PH; Kramm, CM; Müller, HL; Rutkowski, S; von Hoff, K; Frühwald, MC; Gnekow, A; Fleischhack, G; Tippelt, S; Calaminus, G; Monoranu, C-M; Perry, A; Jones, C; Jacques, TS; Radlwimmer, B; Gessi, M; Pietsch, T; Schramm, J; Schackert, G; Westphal, M; Reifenberger, G; Wesseling, P; Weller, M; Collins, VP; Blümcke, I; Bendszus, M; Debus, J; Huang, A; Jabado, N; Northcott, PA; Paulus, W; Gajjar, A; Robinson, GW; Taylor, MD; Jaunmuktane, Z; Ryzhova, M; Platten, M; Unterberg, A; Wick, W; Karajannis, MA; Mittelbronn, M; Acker, T; Hartmann, C; Aldape, K; Schüller, U; Buslei, R; Lichter, P; Kool, M; Herold-Mende, C; Ellison, DW; Hasselblatt, M; Snuderl, M; Brandner, S; Korshunov, A; von Deimling, A; Pfister, SM (2018-03-22)
      Accurate pathological diagnosis is crucial for optimal management of patients with cancer. For the approximately 100 known tumour types of the central nervous system, standardization of the diagnostic process has been shown ...